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ABSTRACT OF THESIS 
 
 
 
 
 
 
 
EFFECTS OF REPEATED CUE EXPOSURE ON CANNBIS CRAVING 
 
Craving is a key element of the cannabis withdrawal syndrome that has been associated 
with continued use and relapse. Although cue-induced cannabis craving has been established in 
single laboratory sessions, procedures to sustain craving over multiple sessions are needed. The 
purpose of the present study was to determine if cue-induced craving responses could be elicited in 
the same subjects across multiple sessions. It was hypothesized that exposure to cannabis cues 
would produce more robust craving responses than exposure to neutral cues and that elicited 
craving responses will be sustained across multiple cue exposures. Five experimental cue exposure 
sessions (1 neutral and 4 cannabis) were conducted. Craving was assessed with the Marijuana 
Craving Questionnaire (MCQ) Short Form, Visual Analog Scale (VAS), Subject-Rated 
Physiological Questionnaire, blood pressure, and heart rate. Results revealed significant effects of 
initial cannabis cue exposure on VAS craving responses and Subject-Rated Physiological measures 
relative to the neutral cue exposure condition. No significant differences were found on MCQ 
composite scores or physiological measures. Craving responses following initial cannabis cue 
exposure were not maintained across sessions. There is a need for a better understanding of the 
factors that contribute to continued drug use despite quit attempts.  
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Chapter One: Significance and Background 
Cannabis (cannabis sativa, cannabis indica) is the most commonly used illicit drug in the 
United States. Results from the 2013 National Survey on Drug Use and Health (NSDUH) 
indicated that 6.9 million Americans were dependent on or abusing illicit drugs; cannabis 
accounted for almost two-thirds (62%) of that population (4.3 million). Of the 2.8 million people 
age 12 or older who used illicit drugs for the first time in 2013, 70.3% reported cannabis as their 
first illicit drug of abuse. In 2013, lifetime prevalence rates for cannabis use for persons aged 12 
or older were 114.7 million (NSDUH, 2013). In 2013, the number of current cannabis users (past 
30 days) age 12 or older was 19.8 million, a number that has been increasing every year since 
2007 (Substance Abuse and Mental Health Services Administration (SAMHSA), 2013). In 2013, 
2.4 million people age 12 or older used cannabis for the first time, an average 6,600 new cannabis 
initiates every day. 1.4 million (58%) of the new cannabis initiates began their use prior to the age 
of 18 (SAMHSA, 2013).  
For the vast majority of individuals, cannabis use does not escalate over time and does 
not interfere with major areas of life functioning. However, approximately 9% of all cannabis 
users do in fact become dependent (National Institute on Drug Abuse (NIDA), 2015). That 
number increases to 17% among those who start smoking cannabis during their teenage years.  
A meta-analysis examining the relationship between cannabis and psychosocial harm 
found that cannabis use was negatively correlated with educational attainment (Macleod et al., 
2004). Similar studies found that adolescent cannabis smokers were less likely to finish high 
school than their non-smoking peers (Silins et al., 2014). Cannabis use before the age of 25 was 
also associated with unemployment, lower income, greater welfare dependence, and lower life 
satisfaction (Ferguson & Boden, 2008; Brook et al., 2013). 
As with other abused drugs, cannabis use significantly impairs motor coordination and 
reaction time. A number of studies have demonstrated that cannabis intoxication impairs motor 
vehicle driving similar to alcohol consumption (Groternhermen et al., 2007; Downey et al., 2013).  
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The 2011 Drug Abuse Warning Network (DAWN Report) stated that cannabis was a 
contributing factor in over 455,000 emergency room visits in the United States, an increase of 
52% from 2004. Thirteen percent of those cannabis related emergency department visits were 
from individuals age 12-17.  
Pharmacokinetics 
The cannabis sativa plant contains over 400 different compounds, approximately 60 of 
which are considered psychoactive. 9-tetrahydrocannabinol (THC) is considered the compound 
that produces the majority of the psychoactive effects associated with cannabis (Gaoni & 
Mechoulam, 1964; ElSohly & Slade, 2005; Ashton, 2001). However, other components of 
cannabis (e.g. cannabidiol) may also contribute to its psychoactive effects (Borgwardt et al., 
2008).  
Smoking is the most common route of administration for 9-THC is smoking. Cannabis 
can be hand rolled into cigarettes (joints) or hollowed out cigar papers (blunts), or smoked using 
glass pipes (bowls) or water pipes (bongs). A typical cannabis cigarette is estimated to contain 
between 500 and 750 mg of 9-THC depending on the potency of the cannabis. This in turn 
delivers anywhere from 2.5-20 mg of 9-THC to the smoker. 9-THC absorbed from smoking has 
a rapid onset and peak blood levels are typically reached within 10 minutes (McLaren et al., 
2008; Pol et al., 2014). 9-THC blood levels drop to 10% of the peak level within one hour. 
However, due to the varying potency among cannabis samples and variability in individual 
smoking processes, the amount of cannabis that reaches the lungs during each smoking session 
can vary significantly (Doweiko, 2015).  
The medicinal properties of cannabis and its components have been the subject of much 
research and debate. Currently, there are two FDA approved THC-based medications, dronabinol 
(Marinol®) and nabilone (Cesamet®). These orally available medications are used for the 
treatment of nausea in patients undergoing cancer chemotherapy and to stimulate appetite in 
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patients with AIDS. Other possible uses of THC-based medications include the treatment of 
spasticity and neuropathic pain in multiple sclerosis patients, and the treatment of severe 
childhood epilepsy and seizure disorders (NIDA, 2015).  
Cannabis can also be recreationally administered through oral absorption by either 
mixing cannabis with food or brewed as tea. Oral absorption is typically slower than smoked 
absorption due to first-pass metabolism (Maykut, 1985). The effects of cannabis are not felt until 
30-120 minutes following ingestion. Because a large amount of cannabis is destroyed by the 
gastrointestinal tract, oral absorption delivers only 4-12% of available cannabis to the blood 
(Ashton, 2001).  
Once absorbed, 9-THC is distributed to the various blood rich organs of the body 
including the heart and the brain. 9-THC is then slowly absorbed over time to the less blood rich 
tissues, such as the body’s fat reserves, where it is stored. Chronic daily abuse of 9-THC results 
in large amounts of 9-THC being stored in the body’s fat cells and users may have 9-THC 
metabolites in their urine for as long as 30 days (Maykut, 1985; McGilveray, 2005).  
The primary site of 9-THC metabolism is in the liver. The half-life of 9-THC depends 
on the level of tolerance that has developed in the individual user. In chronic daily abusers, the 
half-life of 9-THC can vary anywhere from 24 to 96 hours (Doweiko, 2015). 9-THC is almost 
completely metabolized by hepatic cytochrome P450 enzymes to 11-hydroxy-delta-9-THC (the 
active metabolite of THC), which is then converted to the inactive metabolite THCCOOH. The 
inactive metabolite is then excreted in the urine (Huestis, 2007a). 
Mechanism of Action and Neurological Correlates  
9-THC imitates the effects of endocannabinoids, naturally occurring ligands in the brain 
and the periphery. The five known naturally occurring ligands that bind to the endocannabinoid 
receptors are anandamide, virodhamine, N-arachindonoyldopamine, 2-arachidonglycerol, and 
noladin ether. All of the naturally occurring ligands are derivatives of arachidonic acid and have 
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varying degrees of selectivity for the two known cannabinoid receptors, CB-1 and CB-2 (Munro 
et al., 1993; Pertwee, 1998). Endocannabinoid receptors (CB-1 and CB-2) are metabotropic g-
protein coupled. Endocannabinoid receptors are located in large amounts throughout the brain, 
specifically the cortex, hippocampus, basal ganglia, cerebellum, and spinal cord as well as in the 
periphery (Julien et al., 2011).  
Endocannabinoids are synthesized by a sudden influx of calcium to the cell. After their 
release from cells, the endocannabinoid transporter protein transports the endocannabinoids into 
cells where they can be metabolized by fatty acid amide hydrolase (FAAH) (Doweiko, 2015). 
CB-1 receptors are located primarily on presynaptic nerve terminals and inhibit calcium influx 
and facilitate potassium channels resulting in the inhibition of other neurotransmitter release.  
9-THC acts as a partial agonist for the CB-1 and CB-2 receptor sites in the brain and the 
periphery. However, unlike the naturally occurring endocannabinoids, 9-THC has a longer half-
life, is much more potent, and as a result, is more likely to bind to these receptor sites. There are 
large numbers of cannabinoid receptors in the brain. However, 9-THC only activates 
approximately 20% of those receptors. According to receptor reserve theory, since there are such 
a large number of cannabinoid receptor sites, only a small fraction of these sites need to be 
occupied in order to elicit a near maximal effect (Pineda, 1997). In the central nervous system, 
9-THC acts on CB-1 receptors located on presynaptic nerve terminals to inhibit the stimulus 
evoked release of GABA, NE, and ACh. 9-THC reduces the firing rate of these neurons, 
resulting in the calming, sedating effect (Iverson et al., 2009). Although well documented, the 
neurobiological mechanism underlying the subjective effects of 9-THC is not well understood. 
However, like other drugs of abuse, 9-THC appears to produce its euphoric effects through the 
brain’s endogenous opioid neurotransmitter system (Welch, 2005).  
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Pharmacodynamics 
The psychoactive properties of 9-THC are subjective and vary based on individual 
differences and 9-THC potency. Acutely, 9-THC dose dependently produces behavioral effects 
including euphoria, analgesia, sensory distortions, relaxation, and decreased anxiety. 50-60% of 
cannabis users report experiencing mild anxiety following cannabis administration (Julien et al., 
2011). Drug effects typically occur between 10-30 minutes following administration and last 
anywhere from 2-4 hours.  
Physiological effects of 9-THC include decreased blood pressure and increased heart 
rate due to the vasodilation caused by 9-THC’s actions on CB-1 receptors in blood vessels. 
Heart rate is typically increased by 30-50% lasting up to three hours following cannabis use 
(Sidney, 2002; Doweiko, 2015; Lile et al., 2010a). The vasodilation can also result in reddening 
of the eyes. Cannabis smokers also experience various respiratory problems such as increased 
cough, wheezing, acute chest illnesses, and heightened risk of lung infections (Khan et al., 2009).  
Consequences of Cannabis Use 
A growing body of research has found significant associations between 9-THC and 
short-term deficits in cognitive functioning. Short-term cognitive effects of 9-THC include 
problems with memory and learning, distorted perception, and difficulty in thinking and problem 
solving. The negative effects of cannabis on cognitive functioning can last for days or weeks 
following the discontinuation of heavy use (Doweiko, 2015). Additionally, high-potency cannabis 
use can result in sensory distortions in some individuals. Chronic cannabis users are at increased 
risk for experiencing acute psychotic reactions following use. These psychotic reactions tend to 
dissipate after a few hours or days following use and can include delusions and a loss of the sense 
of personal identity (Hall, 1998; Johns, 2001; Van Os, 2002).  
 Previous research determining definitive long-term consequences of cannabis use has 
been limited. This is mostly due to poly-substance use and variations in medical and physical 
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health history among participants (NIDA, 2015). However, in a recent longitudinal study, over 
1,000 individuals were followed from birth to 38 years old. At five waves of data collection 
starting at age 18, cannabis use was assessed. Results from this study found that frequent and 
persistent adolescent cannabis use was associated with neuropsychological decline, specifically, a 
decrease of eight points in average IQ score. Furthermore, following cessation of cannabis use in 
adulthood, participants IQ scores did not improve (Meier et al., 2012).  Additionally, a review of 
48 studies found that chronic cannabis use has been associated with reduced chances of finishing 
high school or obtaining a degree (Macleod et al., 2004; Sillins, 2014).  
Cannabis Use Disorder  
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 
has defined Cannabis Use Disorder (CUD) as “a problematic pattern of cannabis use leading to 
clinically significant impairment or distress” defined by the presence of at least 2 of 11 listed 
criteria occurring within a 12 month period of time. Some of the DSM-5 criteria for CUD 
include: craving, failure to fulfill major role obligations, tolerance, and withdrawal.  
DSM-5 was the first edition to recognize cannabis withdrawal as diagnostic criteria. 
Common withdrawal symptoms include irritability, anxiety, sleep difficulty, restlessness, and 
depressed mood. Withdrawal symptoms occur in over 50% of users who discontinue cannabis 
use. Withdrawal symptoms usually begin within 48 hours of cessation of use and can last 
anywhere from 2-19 days (Julien et al., 2011). Despite the noted withdrawal reactions, 
withdrawal symptoms experienced with cannabis are far less intense than those experienced with 
other drugs of abuse such as alcohol, benzodiazepines, or opiates. However, withdrawal has been 
associated with repeated cannabis use and users report withdrawal symptoms as a trigger for 
relapse during quit attempts (Haney et al., 2013a; 2004; Cornelius et al., 2008).  
Current Treatment Modalities  
Prior to 1994, there were no published controlled research studies focusing on the 
treatment of cannabis abuse or dependence (Steinberg et al., 2005). This may be due to previous 
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misconceptions that cannabis use did not lead to dependence and that there were no adverse 
effects associated with cannabis misuse. We now know that roughly 10% of people who use 
cannabis become daily users (McRae et al., 2003). Coffey and colleagues (2002) found that 
people who smoke cannabis more than once a week were at a significant risk for dependence. In 
the 1990s, the number of people who sought treatment for cannabis dependence more than 
doubled. As a result, there was a significant increase in the development of treatment 
interventions focusing on cannabis dependence, including both behavioral interventions and 
pharmacotherapies.  
Behavioral Interventions. Overall, behavioral interventions such as motivational 
enhancement therapy (MET) (Copeland et al., 2001), cognitive-behavioral therapy (CBT) 
(Stephens et al., 1994), contingency management (CM) (Budney et al., 2000; 2006), and family-
based treatments, have reduced cannabis use and increased abstinence relative to delayed-
treatment control conditions. The Marijuana Treatment Project (MTP), a large multi-site study, 
examined the efficacy of treatment outcomes from three different behavioral interventions with 
450 ethnically diverse cannabis dependent adults. Results from the MTP suggest that both a two-
session MET treatment and a nine-session treatment incorporating MET, coping skills training, 
and case management were significantly more effective in reducing cannabis use than a delayed-
treatment control condition. Additionally, cannabis dependence and anxiety symptoms were 
reduced following both the two- and nine-session treatment interventions, with the nine-session 
intervention showing the greatest improvement (Steinberg et al., 2005). Unfortunately, long-term 
success rates of behavioral interventions of CUDs are limited. Across several behavioral 
intervention studies, only 10-30% of individuals remain abstinent after one year (Budney et al., 
2007a). Because behavioral therapies have shown limited success, there is a recognized need for 
research on the development of pharmacotherapies to assist treatment seekers with the initiation 
and maintenance of abstinence. 
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Pharmacotherapies. Currently, there are no FDA approved medications for the 
treatment of cannabis dependence or for the management of cannabis withdrawal or craving. 
Research studies and subsequent pharmacotherapies have been developed for the treatment of 
alcohol, nicotine, and opioid dependence. However, until recently, research efforts focusing on 
pharmacotherapies for cannabis use disorders have been minimal by comparison. Laboratory 
studies have been designed to examine the efficacy of several medications in the attenuation of 
cannabis withdrawal symptoms, subjective and reinforcing effects, and to prevent relapse.  
Dronabinol. Dronabinol is chemically synthesized 9-THC and acts as a partial agonist. 
Dronabinol is available under the trade name Marinol® in 2.5, 5, or 10 mg capsules for oral 
administration. Marinol® is used for stimulating appetite and preventing weight loss in patients 
with AIDS and treating nausea and vomiting caused by cancer chemotherapy. For these reasons, 
dronabinol has been used in laboratory settings as a potential medication adjunct for cannabis 
relapse and withdrawal.  
Laboratory studies have shown that varying doses of dronabinol (10, 20, and 30 mg) 
administered multiple times daily attenuate withdrawal symptoms typically associated with CUDs 
(Haney et al., 2004; 2008; Budney et al., 2007b). In a similar study by Vandrey and colleagues 
(2013), daily cannabis smokers were given oral doses of dronabinol (0, 30, 60, and 120 mg) for 
five days. On the fifth day of dronabinol maintenance, subjects smoked five puffs of a cannabis 
cigarette. Results showed that dronabinol dose-dependently decreased cannabis withdrawal. 
Similar results were demonstrated by Levin and colleagues (2011). In this 12-week randomized 
placebo-controlled trial, 156 cannabis dependent adults were administered 20 mg twice daily of 
dronabinol or placebo. Results showed that dronabinol significantly improved treatment retention 
and withdrawal symptoms relative to placebo. However, dronabinol did not significantly effect 
post-treatment cannabis use or abstinence rates.  
 Dronabinol has also been shown to attenuate the subjective effects of smoked cannabis. 
In one such study by Hart and colleagues, (2002) healthy cannabis dependent individuals were 
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given oral doses of dronabinol (either 0, 10, or 20 mg) for three days followed by three days of 
placebo maintenance. Relative to placebo, dronabinol maintenance significantly decreased 
subjective reporting of “Good Drug Effect” and “High” following smoked cannabis 
administration (1.8% 9-THC). Other studies however, have failed to demonstrate a reduction in 
subject effects of smoked cannabis following dronabinol administration (Vandrey, 2013).  
Nabilone. Nabilone is a synthetic analog of THC that acts as a CB-1 agonist. Nabilone is 
currently used for the control of nausea and vomiting caused by chemotherapy. Drug 
discrimination studies show that nabilone substituted for dronabinol (Lile et al., 2010b). For these 
reasons, nabilone has been used in laboratory settings as a potential medication adjunct for 
cannabis relapse and withdrawal. In one such study by Haney and colleagues (2013b), healthy 
cannabis dependent individuals were given oral doses of nabilone (0, 6, and 8 mg/day) under both 
placebo and active cannabis self-administration conditions. Both active nabilone conditions 
attenuated cannabis self-administration and decreased withdrawal symptoms.  
Naltrexone. Naltrexone acts as an opioid antagonist at all three opioid receptors, with the 
highest affinity for the μ opioid receptor. Preclinical research has demonstrated that naltrexone 
blocks the effects of cannabis (see Weinstein & Gorelick, 2011 for review). In cannabis users, 
results of naltrexone use have been mixed. Previous human studies have demonstrated that acute 
pretreatment of naltrexone actually increased the positive subjective effects of cannabis (Cooper 
& Haney, 2010). Other studies have shown that naltrexone maintenance decreases cannabis self-
administration and subjective VAS ratings of “Good Effect” (Haney et al., 2015).  
Rimonabant. Rimonabant acts as a selective, potent, and orally active CB-1 receptor 
antagonist. Rimonabant was developed as a CB-1 antagonist and proved successful at blocking 
the effects of 9-THC in pre-clinical studies (Tseng & Craft, 2004). Rimonabant has been 
approved for use in Europe and other countries; however it has not been approved in the United 
States. Acute administration of rimonabant has been shown to reduce subjective drug effects in 
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cannabis dependent individuals (Huestis et al., 2001). In a double-blind, randomized trial, 
subjects received either 0, 40, or 90 mg of rimonabant. During two laboratory sessions, subjects 
smoked either active or placebo cannabis. Both active rimonabant conditions attenuated the acute 
physiological effects of smoked cannabis and acutely attenuated subjective responses (Huestis et 
al., 2007b).  
Nabiximols. Nabiximols is a cannabinoid receptor agonist and the first cannabis-based 
medication licensed in the UK. It is currently approved for muscle spasticity related to multiple 
sclerosis. Nabiximols is an oromucosal spray containing 9-THC and cannabidiol. Because of its 
route of administration, nabiximols has a more predictable pharmacokinetic profile than oral THC 
and has a lower abuse potential than dronabinol (Schoedel et al. 2011). In a double-blind, 
randomized, placebo-controlled clinical inpatient trial, subjects were given either active 
nabiximols (maximum daily dose, 86.4 mg of Δ9-tetrahydrocannabinol and 80 mg of 
cannabidiol) or placebo. Acutely, nabiximols significantly reduced cannabis withdrawal relative 
to placebo. Additionally, nabiximols improved patient retention in treatment (Allsop et al., 2014).  
 Other possible pharmacotherapy agents investigated have included buspirone, lithium, 
lofexidine, N-acetyl cycteine (NAC), and gabapentin (see Vandrey & Haney, 2009 for review; 
see Balter et al., 2014 for review). NAC and gabapentin in particular, have been tested in 
randomized control trials. In an 8-week double-blind randomized placebo-controlled trial, 116 
cannabis-dependent adolescents received either 1200 mg of NAC or placebo. Results showed that 
adolescents in the NAC treatment condition had more than twice the odds relative to placebo of 
having a THC negative urine toxicology screen during treatment (Gray et al., 2012).  In a 12-
week double-blind randomized placebo-controlled trial, cannabis-dependent adults received 
either 1200 mg of gabapentin or placebo. Results showed that gabapentin significantly reduced 
cannabis use and cannabis related withdrawal symptoms relative to placebo (Mason et al., 2012).  
There is a need for increased research on the development of more effective 
pharmacotherapies for CUDs. Although numerous possible pharmacotherapy agents have been 
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studied, none have been approved by the FDA for the treatment of CUDs. Research has shown 
that a combination of pharmacotherapy and behavioral interventions result in greater treatment 
improvement outcomes relative to either intervention alone (Vandrey & Haney 2009).  
Craving and Cue Exposure 
 It is generally understood that an interaction between various biological, psychological, 
and social factors contribute to addiction and relapse. One of the primary goals of drug treatment 
programs is for the individual to achieve and maintain abstinence from drug use. Drug craving is 
an intense, emotional, and physical experience resulting in an impulse to use drugs. Drug craving 
can interfere with an individual’s ability to maintain abstinence after quit attempts. Craving can 
elicit physiological responses similar to those associated with substance abuse including anxiety, 
increased heart rate, and sweaty palms. Craving for cannabis is a key element of the withdrawal 
syndrome that has been characterized in abstinent individuals with a history of chronic use. 
Craving has been associated with continued substance use and relapse during quit attempts in the 
natural environment, but not causally linked in a laboratory setting (Drummond et al., 2000; 
Weiss, 2005; Carter & Tiffany, 1999; Childress et al., 1993).  
Exposure to drug cues (e.g., handling drug paraphernalia, audio and visual drug-related 
stimuli) induces robust subjective reports of craving. Cue-induced craving for cocaine (Robbins 
et al., 1992), opioids (Hyman et al., 2007), alcohol (Fox et al., 2007), and tobacco (Ferguson & 
Shiffman, 2009) has been established in laboratory settings. Previous research has also 
demonstrated increased subjective craving responses in cannabis dependent individuals following 
exposure to cannabis cues.  
 In one such study, daily cannabis users and a control group of cannabis-naïve individuals 
were exposed to both neutral cues and cannabis cues in a single laboratory session. During the 
neutral phase, subjects were exposed to a variety of neutral objects (i.e., pencils, eraser, ruler). 
Subjects were instructed to handle and smell the objects while viewing a videotape of nature 
scenes. After a brief rest period, the cannabis phase began. During this phase, subjects were 
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exposed to a variety of cannabis-related paraphernalia (i.e., bong, pipe, papers). Subjects were 
instructed to handle and smell the objects while viewing a videotape of young adults smoking. 
Mood and subjective craving effects were measured at baseline and following both the neutral 
and cannabis phases. Responses on the craving measures increased from baseline following 
cannabis cues relative to neutral cues, but only for the cannabis dependent group (Lundahl & 
Johanson, 2011). Similar single session studies examining cue reactivity in cannabis smokers also 
found greater subjective craving responses during the presentation of cannabis cues relative to 
neutral cues (Nickerson et al., 2011, Gray et al., 2008; 2011; Bordnick et al., 2009; McRae-Clark 
et al., 2011). Skin conductance also increased during the presentation of cannabis cues relative to 
neutral cues (Gray et al., 2008; 2011; Wolfling et al., 2008).  
Successful use of a cue-induced craving within-subjects design has been demonstrated in 
a recent study by Lundhal and Greenwald (2015). In this study, 14 cannabis dependent 
individuals were pretreated with placebo, 10, or 20 mg of oral THC. Following THC 
administration, subjects were exposed to a 10 minute neutral cue exposure followed by a 10 
minute cannabis cue exposure. Results showed significant increases on the Marijuana Craving 
Questionnaire (MCQ) compulsivity scores following cannabis cues relative to neutral cues. 
Additionally, significant increases were found on Visual Analog Scale (VAS) items “desire to use 
marijuana,” “urge to smoke marijuana,” and “craving for marijuana.”  
Behavioral Models of Drug Use and Craving 
Behavioral models of substance abuse are primarily influenced by B. F. Skinner’s operant 
learning theory and Ivan Pavlov’s classical conditioning theory. Operant conditioning models are 
based on the notion that drug use and addiction are maintained through general learning and 
reinforcement principles. According to this model, drug-taking behaviors are initiated and 
maintained because of the positive reinforcing effects of drug use. Following cessation of drug 
use, individuals are likely to experience increased discomfort associated with craving and 
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withdrawal. According to the operant learning model, relapse to drug use can be understood as a 
means of reducing the negative discomfort associated with craving and withdrawal.  
Ivan Pavlov’s classical conditioning model is useful in understanding the processes 
involved in cue-induced craving. In its most basic form, a neutral stimulus (NS) is paired with an 
unconditioned stimulus (US) that innately elicits a central nervous system physiological response 
(UR). When administered alone, the NS does not elicit the physiological response. However, 
through repeated pairings of the NS and US, the NS becomes a conditioned stimulus (CS) 
eliciting a conditioned response (CR) (Seigel & Ramos, 2002). Through the process of classical 
conditioning, stimuli that have been previously associated with drug taking behavior (e.g., drug 
paraphernalia) act as conditioned stimuli in absence of the actual drug of abuse. The classical 
conditioning model demonstrates how through repeated pairings, drug cues serve as 
discriminative stimuli (paraphernalia, environment, viewing drug use, etc.) and elicit 
neurobiological changes resulting in drug craving symptoms (see Carter & Tiffany, 1999 for 
review).  
Cannabis dependence is a chronically relapsing condition (Koob, 2006; Taylor et al., 
2009). Craving is a key element in relapse and can occur following periods of abstinence. In cue 
exposure treatment models, a client is presented with drug cues; however, the client is prevented 
from taking drugs. The theory is that this extinction procedure, overtime, can lead to breaking the 
classical conditioning pairing resulting in decreases in reactivity to drug cues. Results, however, 
have been mixed. Preclinical research has demonstrated that cue exposure models can be used to 
attenuate drug-seeking behavior (Buffalari et al., 2013; Kearns et al., 2012). However, other 
preclinical studies have not shown reduction in drug-seeking behavior (Crombag et al., 2002). 
Similarly, in humans, the results of cue exposure therapy (CET) are mixed. Some CET studies 
show promise as an adjunct treatment (Lee et al., 2007; Santa Ana et al., 2015), while others 
actually show increased relapse rates compared to placebo (Marissen et al., 2006).  
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Craving as a Construct 
Although previous literature highlighted the importance of cue-induced craving, the 
specific construct of craving and its validity as a laboratory measure have been widely debated. 
One of the major problems when exploring craving as a construct is variation in methodology 
used. Drug craving can be measured through self-report questionnaires, physiological indices 
(i.e., blood pressure, heart rate), or behavioral paradigms (i.e., self-administration). As a result, 
standard methods of measuring subjective craving in laboratory settings have yet to be 
established (Marlatt 1990, Tiffany et al., 2000). Another issue arises when discussing the 
variations in self-reported craving. Specifically, researchers differ as to whether craving should be 
assessed across a broad continuum (i.e., Visual Analog Scale) or with a more limited 
characterization (i.e., Marijuana Craving Questionnaire). As a result, construct validity has been 
almost impossible to establish (Sayette, 2000).  
The operational definitions notwithstanding, exposure to drug cues have been shown to 
increase subjective reports of craving across all drugs of abuse in laboratory settings. There is a 
need for a better understanding of the factors that contribute to continued drug use despite quit 
attempts in order to develop models and procedures for the evaluation of behavioral and 
pharmacological therapies for treatment. The disproportionate amount of CUDs and new initiates 
relative to treatment seekers highlights the importance of developing new treatment modalities for 
cannabis use disorders.  
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Chapter Two: Purpose of Project 
The purpose of the present protocol was to test whether a cue reactivity procedure could 
elicit a craving response within-subjects in a laboratory setting and to see whether those craving 
responses could be sustained across multiple sessions. In general, previous cue reactivity 
paradigms have used group designs and have not reported on the test-retest reliability of the 
craving response to drug cues. Considering the strength of within-subjects designs in medication 
development research, an important step would be to demonstrate that cue-induced craving 
responses of similar magnitude can be elicited in the same subjects across multiple sessions.  
Craving can be an important contributor to relapse following quit attempts. Subjective 
drug craving is an important component of the addiction process that is not captured through 
other studied laboratory models of addiction such as pharmacological selectivity (Lile et al, 2011; 
2012), self-administration (Haney et al., 1997), or attentional bias (Field & Cox, 2008). A better 
understanding of the craving processes is important in helping individuals maintain sobriety 
following quit attempts.  
The present study focused on the effects of cue exposure on subjective craving. Drug 
cravings are intense subjective experiences that can be triggered by internal stimuli or external 
drug cues. Because of the subjective nature of craving responses, the present study examined 
individual subjective responses to cue-induced craving.  
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Chapter Three: Hypothesis 
Behavioral 
Exposure to cannabis cues will produce more robust craving responses than exposure to 
neutral cues. Following neutral cue presentation, daily cannabis smokers will report no change on 
the subject-rated craving responses from baseline. Changes on other VAS items will not be 
affected. Following cannabis cue presentation, daily cannabis smokers will report an increase on 
subject-rated craving responses from baseline. It was also hypothesized that subject rated craving 
responses to cannabis cues would be sustained across multiple cue exposure sessions.  
Physiological 
Consistent with previous studies, no changes from baseline are anticipated following the 
neutral and cannabis cue presentations on either the subject rated physiological questionnaires or 
cardiovascular physiological measures.  
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Chapter 4: Method 
The proposed experiment and informed consent document have been approved by the 
Institutional Review Board of the University of Kentucky Medical Center. 
Subject Recruitment 
Subjects were recruited through local community internet, newspaper and radio 
advertisements, bulletin board postings, and word-of-mouth. Inclusion in the study was 
contingent on daily cannabis use. Subjects needed to be between the ages of 18-50 and in good 
health except for their drug use. Tactile, auditory, or visual conditions that would impact 
perception of drug cues, history of serious physical or psychiatric disease, and current use of 
psychiatric medications were exclusionary. Additionally, subjects who wished to seek treatment 
for their drug use were also excluded from the study. During the recruitment phase, subjects were 
not informed of the specific inclusion/exclusion criteria noted above.  
Subjects made initial contact with the research facility either by phone or through the 
internet (http://rrf.research.uky.edu/). During this initial contact, a brief screening regarding the 
inclusion/exclusion criteria was conducted. Prospective subjects were then provided with 
additional details of the study and were invited to begin the screening component. All potential 
subjects who were identified using the recruitment methods noted above received oral and written 
descriptions of the study prior to providing written consent.  
Payment 
Subjects were paid $20 for completing the screening packet. Subjects were paid $20 for a 
practice session and $20 for each of the five subsequent experimental sessions. Subjects received 
an additional $20 completion allowance for each of the six sessions (1 practice + 5 experimental) 
if they completed the entire experiment. Subjects who were terminated for medical reasons 
received all of the money they earned through their termination date as well as the $20 
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completion allowance. The maximum amount of money a subject could receive was $260 ($240 
for study participation + $20 for screening).  
Screening 
Initial in-person screenings lasted between one and three hours and were conducted at the 
UK Residential Research Facility (RRF). During the initial screening, subjects were given the 
IRB-approved informed consent document to read and sign. Subjects were advised of the 
voluntary nature of participation and of their right to withdraw from the project at any time. 
Subjects were also advised of aspects of the study protocol including potential study risks and 
benefits, payment, confidentiality of information, and rights as a research participant. Subjects 
were required to abstain from cannabis use on the day of, and from alcohol use 12 hours prior to 
the experimental session. Repeated alcohol and drug violations resulted in dismissal from study 
participation. Study investigators addressed any questions or concerns the subject had prior to 
obtaining consent. Subjects were informed that staff members were available at any point during 
the study to answer questions or explain study procedures.  
Once the subject agreed to participate in the present protocol, a breathalyzer and urine 
toxicology screen was conducted. Breath samples positive for alcohol or a urine sample positive 
for drugs of abuse (other than cannabis) precluded the subject from participation in screening that 
day. Subjects were also asked to provide an expired air sample that was tested for the presence of 
carbon monoxide (CO).  
 Subjects then completed computerized screening assessments which included 
information about: demographics, family medical history, past and present medical and mental 
health history, past and present drug and cannabis use history, and the Structured Clinical 
Interview for DSM-IV (SCID). Subjects then filled out a Cannabis Use Calendar (Appendix A). 
This was followed by an assessment of vital statistics including heart rate, blood pressure, and 
weight. Subjects were paid for their participation in the initial screening.  
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Of note, screening procedures for behavioral pharmacology studies conducted at the RRF 
typically include a physical health screening (blood/urine analysis and ECG) with results 
reviewed by a study physician. However, because of the minimal risk associated with the protocol 
and because drugs were not administered, these procedures were not included. 
Experimental Procedures 
Experimental procedures were conducted on an outpatient basis at the RRF. Upon arrival, 
subjects relinquished their keys, watches, and mobile phones, which were stored securely until 
the end of the session. A field sobriety test was then conducted to ensure that subjects were not 
intoxicated prior to session initiation. A breathalyzer and urine toxicology screen were conducted. 
Breath samples positive for alcohol or a urine sample positive for drugs of abuse (other than 
cannabis) precluded the subject from participation in the experimental session. Urine samples 
from female subjects that were positive for pregnancy resulted in dismissal from the study.  
Subjects then completed the Sign-In Questionnaire that assessed past 24-hour nicotine, 
alcohol, caffeine, and cannabis use, medication use since their last session, and any changes in 
their normal routine. The Sign-In Questionnaire can be found in Appendix B. Subjects who 
smoked cigarettes were then allowed to smoke a single cigarette before the session began. 
Subjects were not allowed to smoke again until the end of the experimental session.  
The study consisted of one practice and five experimental (1 neutral + 4 cannabis cue) 
sessions. Experimental session rooms at the RRF were equipped with Macintosh computers 
programmed to present the sessions tasks in a prearranged sequence. Data were stored in files 
coded for participant identity protection. Files were backed up at the end of each session.  
Practice session. Subjects completed a practice session prior to beginning experimental 
sessions to familiarize them with the behavioral tasks and timeline of the experimental protocol 
described below. During these practice sessions, subjects were exposed to the neutral, but not 
cannabis, cue condition. 
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Experimental sessions. Subjects completed five experimental sessions after successfully 
completing the practice session. Experimental sessions included behavioral tasks as well as either 
a cannabis or neutral cue presentation. The order of cue presentations was randomly assigned. 
The timeline for the experimental sessions is shown in Table 4.1 below. The complete Study Run 
Sheet is shown in Appendix C.  
Table 4.1. Daily Schedule Timeline 
Time Procedure 
-30 Check in Procedures (BAC, CO, urine toxicology, weight, Sign-In 
Questionnaire) 
0 MCQ, VAS, HR, BP 
5 Cue Exposure, Physiological Questionnaire, MCQ, VAS, HR, BP 
30 MCQ, VAS, HR, BP 
60 MCQ, VAS, HR, BP 
  Check out Procedures 
 
Physiological measures assessed during the four noted time points included heart rate and 
blood pressure. Subjective responses were assessed during the four noted time points with the 
Marijuana Craving Questionnaire (MCQ) Short Form and the Visual Analog Scale (VAS). 
Immediately following the cue presentation, subjects filled out an 11-item Subject-Rated 
Physiological Questionnaire that was locally developed.  
Physiological Response 
Heart rate and blood pressure were measured using a Dinamap digital monitor (Critikon, 
Pro 200, Tampa, FL). Vital signs were measured during the practice and experimental sessions at 
baseline, immediately following the cue presentation, 30 minutes following baseline, and 60 
minutes following baseline.  
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Subject-Rated Drug-Effect Questionnaires 
Marijuana Craving Questionnaire (MCQ) Short Form. The Marijuana Craving 
Questionnaire (MCQ) was developed and validated as a 47-item self-report assessment 
(Heishman et al., 2001). In 2009, a short form of the questionnaire was developed as a 12-item 
assessment divided into four subscales: compulsivity, emotionality, expectancy, and 
purposefulness. There are three MCQ items in each of the four subscales. Subjects were shown 
statements regarding cannabis use and anticipated effects on a computer screen and were asked to 
indicate their answer by using a computer mouse to select one of 7 options ranging from 
“strongly disagree” (scored as 1) to “strongly agree” (scored as 7). Composite scores are 
produced for each subscale, with a maximum score of 21 on each subscale. The MCQ short form 
is reprinted in Appendix D.  
Visual Analog Scales (VAS). Subjects were asked to rate themselves across nine 
different dimensions (e.g. shaky or jittery, restless) and five self-report craving items by placing a 
mark on a 100-unit line with the left endpoint of the continuum labeled “Not at all” and the right 
endpoint labeled “Extremely.” Each item was scored by how many millimeters the participant 
placed the marker from the left end of the scale indicating “Not at all” (scored as 0) to the right 
end of the scale indicating “Extremely” (scored as 100). The maximum possible score for any of 
the VAS items was 100. Due to a possible ceiling effect (i.e., craving levels are elevated and 
therefore insensitive to the experimental manipulation), subjects who scored greater than or equal 
to 50 out of 100 on the VAS “Cannabis craving” item during the neutral session were not 
included in the present analysis. VAS items are found in Appendix E.  
Subject-Rated Physiological Questionnaire. The Subject-Rated Physiological 
Questionnaire was administered one time only immediately following the cue exposure.  Subjects 
were asked to rate how strongly they experienced 11 different physiological symptoms (e.g. faster 
heart rate, rapid breathing). Subjects were asked rate how they were thinking or feeling during the 
time they were handling the objects during the cue exposure. Items were rated on a five-point 
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scale ranging from “Not at all” (scored as 0) to “All of the time” (scored as 4). The Subject-Rated 
Physiological Questionnaire is reprinted in Appendix F.  
Cue Exposure Conditions 
Cue exposure conditions lasted eight minutes and included a three-minute tactile cue, a 
one-minute imagery prompt, and a four-minute visual cue. For the tactile cue, an opaque pitcher 
containing either neutral or cannabis physical cues was placed on the participant’s desk at the 
beginning of each of the cue exposure sessions. Following each cue presentation, subjects 
completed the Subject-Rated Physiological Questionnaire, MCQ, and VAS. In addition, heart rate 
and blood pressure were taken.  
Neutral cue exposure. Neutral cue exposure instructions were displayed on the computer 
screen. The neutral cue exposure timeline was as follows: 
 
Time (seconds)   Instructions 
 0 Please remove the cover and look at the objects. 
 60 Please pick up and hold the objects. 
 180 Please place the objects back on the tray and replace the cover. 
 210  Please think of a recent time and place where you were most relaxed. 
 240 Video starts: (run time: 4 minutes) 
 480 Video ends: Subject-Rated Physiological Questionnaire, MCQ, VAS, HR, BP 
 
Objects presented during the neutral cue exposure included a variety of school supplies 
(e.g. pencils, erasers, a ruler). The video presented during the neutral cue was of various nature 
scenes (e.g. waterfalls, mountains). At the conclusion of the video the assessments began.  
Cannabis cue exposure. Cannabis cue exposure instructions were displayed on the 
computer screen. The cannabis cue exposure timeline was as follows: 
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Time (seconds)   Instructions 
 0 Please remove the cover and look at the objects. 
 60 Please pick up and hold the objects. 
 180 Please place the objects back on the tray and replace the cover. 
 210 Please think of a recent time and place when you enjoyed smoking cannabis. 
 240 Video starts: (run time: 4 minutes) 
 480 Video ends: Subject-Rated Physiological Questionnaire, MCQ, VAS, HR, BP 
 
  Objects presented during the cannabis cue exposure were a variety of cannabis 
paraphernalia (e.g., a rolled joint containing an inactive cannabis substitute, pipe, rolling papers).  
The video presented during the cannabis cue exposure was of young adults smoking (e.g., 
preparing to smoke, smoking in several different settings). At the conclusion of the video the 
assessments began. 
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Chapter Five: Data Analysis 
Statistical analyses were used to investigate the effects of cue exposure on subjective and 
physiological assessments. For all statistical analyses, effects with p ≤ .05 were considered 
significant. Daily peak effects following cue exposure were analyzed using one-factor, repeated-
measures ANOVA with cue exposure session (cannabis 1, cannabis 2, cannabis 3, cannabis 4, and 
neutral) as factors. If a main effect of session type attained statistical significance, planned 
comparisons of active drug cue exposure session days to the neutral cue exposure session were 
conducted. 
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Chapter Six: Results 
Subjects 
Eleven (5M, 6F) non-treatment-seeking daily cannabis users were included in the present 
analysis. Ages ranged from 19 to 29 years. Seven of the subjects were White; four of the subjects 
were Black. Subjects had been smoking cannabis for an average of six years with a range of 2 
years to 13 years of use. Table 6.1 presents the age, weight, race, self-reported daily caffeine and 
cigarette use, weekly alcohol and cannabis use, and number of years using cannabis for the eleven 
subjects. 
Twenty-two subjects reported to the RRF for the initial screening procedures. Of the 22, 
four were excluded because they did not meet the cannabis use criteria (smoked less than 25 days 
per month), two were excluded because of repeated drug and alcohol abstinence violations, one 
was excluded because of a positive PTSD SCID diagnosis, and one voluntarily discontinued her 
involvement in the study. Of the 14 remaining subjects, three were excluded because of high 
baseline levels of VAS cannabis craving scores. Subject demographic information is presented in 
Table 6.1.  
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Table 6.1. Subject demographic information.  
 
Sex N = 5 M, 6 F 
Race/Ethnicity N = 7 White, 4 Black 
                                                                 Mean (SD) 
Age 21.13 (3.52) 
Weight (lbs) 154.65 (25.41) 
Marijuana (days/month) 27 (1.68) 
Number of years used marijuana 6 (3.79) 
Alcohol (days/week) 1.67 (1.31) 
Cigarettes (per day) 2.1 (3.38) 
Caffeine (mg/day) 140.8 (83.83) 
 
Physiological response. No significant differences were found on physiological 
measures (i.e., BP and heart rate) following cannabis cue conditions relative to the neutral cue 
condition. F-values are shown in Table 6.2. 
Marijuana Craving Questionnaire. No significant cue exposure effects were found for 
any of the MCQ composite scores. F-values are shown in Table 6.2. 
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Table 6.2. F-values from peak-effect analysis for subject-rated drug-effects measures and 
physiological indices as compared to the neutral session day (Bold indicates a significant F-
value). 
 
Outcome Measures 
 
Physiological Response 
Heart Rate 
Blood Pressure 
Diastolic  
Systolic 
 
Subject-Rated Drug Effect Questionnaires 
Marijuana Craving Questionnaire (MCQ) 
Composite Scores 
Compulsivity 
Emotionality 
Expectancy 
Purposefulness 
 
Visual Analog Scale (VAS) 
I Feel… 
Sedated 
Stimulated 
Nauseated 
Shaky or Jittery 
Restless 
Dizzy 
Difficulty Concentrating 
Anxious 
Nervous 
I Have a Craving For… 
Alcohol 
Tobacco 
Marijuana 
Cocaine 
Opiates 
 
 
 
 
 
 
 
F-Values 
 
 
2.33 (p = 0.07) 
 
2.44 (p = 0.06) 
0.95 
 
 
 
 
0.57 
2.08  
0.17 
1.28 
 
 
 
1.49 
1.23 
0.76 
0.89 
0.92 
1.00 
0.74 
1.19 
0.54 
 
0.68 
2.30 
2.92 (p < 0.05) 
-- 
-- 
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Table 6.2 (continued). F-values from peak-effect analysis for subject-rated drug-effects 
measures and physiological indices as compared to the neutral session day (Bold indicates a 
significant F-value). 
 
Subject-Rated Physiological Questionnaire 
Faster heart rate 
Rapid breathing 
Sweating hands 
Heavy feeling in stomach 
Loud pounding heart 
Tensed muscles 
Cold hands 
Feeling flushed or hot 
Salivating more 
Trembling 
Dry mouth 
 
 
4.04 (p < 0.01) 
1.00 
1.00 
-- 
0.73 
0.43 
1.35 
1.00 
1.97 
-- 
-- 
 
Visual Analog Scale. A one-factor, repeated-measures ANOVA revealed a significant 
effect of cue exposure condition on subjective craving response on the VAS item “I have a 
craving for Marijuana” (F4,40 = 2.92, p < 0.05). Contrasts indicated that the mean score for 
subjects in the initial cannabis cue condition (M = 20.09, SD = 20.26) was significantly higher 
than the mean score for subjects in the neutral cue condition (M = 9.18, SD = 11.46). Results 
showed subjects experienced greater subjective cannabis craving responses following the Day 1 
cannabis cue exposure compared to neutral cue exposure. No significant differences were found 
on subsequent cannabis cue conditions (i.e., day 2-4) relative to the neutral cue condition. Results 
are shown in Figure 6.1. F-values are shown in Table 6.2.   
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Figure 6.1.
 
 
 
Subject-Rated Physiological Questionnaire. A one-factor, repeated-measures ANOVA 
revealed a significant effect of cue exposure condition on subject-rated physiological response 
during the tactile cue presentation. Specifically, subjects reported significant increases in 
subjective awareness of a faster heart rate (F4,40 = 4.04, p < 0.01) following the initial cannabis 
cue condition (M = 1.45, SD = 0.52) as compared to the neutral cue condition (M = 1.00, SD = 
1.00). No significant differences were found on the Subject-Rated Physiological Questionnaire 
responses on subsequent cannabis cue conditions (i.e., day 2-4) relative to the neutral cue 
condition. Results are shown in Figure 6.2. F-values are shown in Table 6.2. 
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Chapter Seven: Conclusion 
 The purpose of the present protocol was to test whether a cue reactivity procedure could 
elicit craving responses in a within-subjects laboratory setting. Additionally, the protocol aimed 
to see whether craving responses could be sustained across multiple experimental laboratory 
sessions. 
 It was hypothesized that exposure to cannabis cues would produce more robust craving 
responses than exposure to neutral cues in daily cannabis smokers in a within-subjects design. It 
was also hypothesized that subject-rated craving responses to cannabis cues would be sustained 
across multiple cannabis cue exposure sessions.  
Results showed that initial cannabis cue exposure significantly increased subjective 
responses of craving compared with neutral cue exposure. These data are in agreement with 
previous research demonstrating increased subjective ratings of craving following drug cue 
exposure (Lundahl et al., 2011; Nickerson et al., 2011; Gray et al., 2008, 2011; Bordnick et al., 
2009; McRae-Clark et al., 2011). Contrary to the hypothesis, the increased craving responses 
following cannabis cue exposure were not maintained across sessions (i.e., days 2-4). In recent 
study by Lundahl and Greenwald (2015), repeated cue exposures successfully elicited increased 
craving responses across multiple session days. A main difference between these studies is that 
Lundahl and Greenwald (2015) administered varying doses of oral THC prior to cue exposure, 
whereas this study did not. The Lundahl analysis focused on the effects of differential oral THC 
pretreatment on cannabis craving across multiple sessions. In contrast, the present study focused 
on the effects of session day on craving responses.  
No significant differences were found on physiological measures (i.e., blood pressure and 
heart rate) following cannabis cue conditions relative to the neutral cue condition. The failure to 
detect changes in heart rate and blood pressure was expected. These data are consistent with 
previous findings (Lundahl et al., 2011; Gray et al., 2008; Nickerson et al., 2011) that did not 
detect cardiovascular physiological changes following cannabis cues relative to neutral cues.  
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Initial cannabis cue exposure did however significantly increased subject-rated 
physiological response of “Faster Heartbeat.” Subjects reported increased awareness of a faster 
heartbeat during the time they were handling the cannabis cue objects relative to the neutral cue 
objects. This outcome is consistent with classical conditioning theory. According to the classical 
conditioning model, conditioned stimuli such as drug cues will, over time, elicit drug-related 
physiological responses because of their repeated pairings with drug use.  
Despite this subjective report of increased heartbeat, there were no actual increases in 
physiological measures of heart rate following cannabis cue exposure. One possible explanation 
could be that subjects detected a slight increase in heart rate that was not statistically significant. 
A second possible explanation could be that the physiological measure of heart rate was done at 
the end of the time point following the completion of the Subject-Rated Physiological 
Questionnaire, MCQ, and VAS. This one to two minute time lapse between the Subject-Rated 
Physiological Questionnaire and the physiological assessment might account for why the 
physiological change in heart rate was not detected. Future studies might seek to assess 
physiological measures closer to the completion of the cue exposure.  
No significant differences were found on type of cue exposure session for any of the four 
MCQ subscales. The failure to observe cue-induced changes in MCQ ratings is inconsistent with 
previous studies. Previous research has demonstrated an increase in subjective ratings on the 
MCQ following active cannabis cue exposure (Lundahl et al., 2011; 2015; Gray et al., 2008; 
McRae-Clark et al., 2011). One possible explanation for this discrepancy could be due to 
differences of the cannabis cues used. For example, Gray and colleagues (2008) had participants 
“flick” a lighter during the tactile cue presentation, allowing for a more active involvement with 
the cannabis cues. Previous studies have also included olfactory cues and asked participants to 
smell a cannabis cigarette during cannabis cue exposure (Gray et al., 2008; Lundahl et al., 2011). 
These differences may have led to differences in subject-rated impact and incentive salience 
attributed to the cannabis cues.  
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 Several limitations should be considered. At no point during the study were subjects 
given access to smoke cannabis. Cannabis administration following cue exposure might have 
increased the salience of the cannabis cues. This in turn might have resulted in greater subjective 
craving responses following cannabis cue exposure.  A second limitation of this study is the 
repetitive nature of the cannabis cue conditions. Previous research has focused on craving 
responses in single laboratory sessions. To our knowledge, this is the first study to examine the 
effects of multiple cue exposure sessions on cannabis craving. Participants in the present study 
were shown the same objects and video clip during each of the four cannabis cue exposure 
conditions. Subjects could have become sensitized to the repeated cannabis cue objects over time. 
This could explain the decrease in craving responses following the initial cannabis cue condition 
(i.e., days 2-4).  
Another limitation was the lack of variability of cannabis paraphernalia during the 
cannabis cue exposure. Cannabis paraphernalia presented during the cannabis cue exposure 
condition consisted of a rolled joint, pipe, lighter, and rolling papers. The video clip involved 
someone rolling a joint and someone smoking a pipe. Since type of smoking preference is so 
varied (pipe, water pipe, blunt, joint, etc.), capturing a broader array of smoking preferences may 
tap into a more specific individualized cue responses.  
 Another possible limitation was the characteristics of the subjects enrolled in the study. 
Subjects recruited for the study were high functioning. The majority had full-time jobs, some had 
children, and some were enrolled as full time students. The majority of the subjects enrolled 
incorporated cannabis smoking into their otherwise full, daily routine. Cannabis cue exposure 
might differentially impact subjects who smoke cannabis multiple times throughout the day 
compared with subjects who, for example, smoke cannabis once a day or before they go to sleep. 
Previous research has shown differences in subjective responses to Δ9-THC between frequent and 
infrequent cannabis users (Kirk and De Wit, 1999). Although subjects in the present study were 
required to smoke cannabis at least 25 days per month, subjects varied in the daily amount of 
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cannabis smoked, ranging from 1 to 6 times per day. Additionally, subjects in the present study 
reported lifetime cannabis use ranging from 2 years to 13 years. Future research should explore 
both daily and lifetime differences in cannabis use patterns as it relates to craving and cue 
exposure.  
 Future research should use more salient cannabis cues during the active drug cue 
exposure. For example, using a cannabis that is filled with actual cannabis may increase craving 
responses since it would have a more realistic look, feel, and smell than using a cannabis-like 
substitute. The closer laboratory cue exposure conditions can get to real world drug taking 
behavior, the greater likelihood craving responses will be increased. Additionally, future cue 
exposure studies should look to individualize cue exposure conditions and try to make laboratory 
conditions mimic subjects’ real world drug taking situations as closely as possible.  
There is limited research in the field directly linking cannabis craving with drug taking 
behavior. Craving has been associated with continued substance use and relapse during quit 
attempts in the natural environment. The present study was designed to be the first of a larger 
three-phase study. The purpose of the initial phase was to establish a within-subjects laboratory 
procedure where drug cues would elicit increased craving responses. The second phase is 
designed to establish causation between drug craving and relapse through a self-administration 
paradigm. The third phase of the study is designed to use the established procedure to quickly 
screen pharmacotherapies for CUDs. A better understanding of the factors that contribute to 
continued drug use despite quit attempts is important because such an understanding will help to 
develop models and procedures for the evaluation of behavioral and pharmacological therapies 
for treatment. 
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Appendix A. 
Cannabis Use Calendar 
 
Have you ever used marijuana? ____Yes  ____No 
 
How have you used marijuana?    ____ Oral ____ Smoking 
 
Which method was most typical? ______________________________ 
 
On the calendar, please circle the days that you used marijuana during the past 4 weeks and 
indicate how many times that you used marijuana on that day: 
 
Sun Mon Tue Wed Thu Fri Sat 
Sun Mon Tue Wed Thu Fri Sat 
Sun Mon Tue Wed Thu Fri Sat 
Sun Mon Tue Wed Thu Fri Sat 
Sun Mon Tue Wed Thu Fri Sat 
 
How many days in the last year have you used marijuana?   
 
If you have not used marijuana in the past year, when was your last use? 
  
 
Which of the following best describes your typical use of marijuana: 
  
____ non-medical (e.g., to party, to get high, to relax)?  
 Identify reason ________________________________________________ 
____ prescribed by your doctor for a medical purpose? 
 Identify medical purpose _________________________________________ 
 
Has your marijuana use ever been a problem for you or for others?  ____Yes  ____No  
 
If Yes, explain _________________________________________________________ 
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Appendix B. 
Sign-In Questionnaire 
 
1. How many hours of sleep did you get last night? ___________________ 
 
2. Have you used any nicotine products in the last 24 hours?  Yes No 
 
If you answered “yes”, how many cigarettes have you used in the last 24 hours? ____________ 
 
3. Have you had any alcohol in the last 12 hours?   Yes No 
 
If you answered “yes”, at what time did you have your last drink? ____________ 
 
4. Have you had any cannabis in the last 24 hours?   Yes No 
 
If you answered “yes”, at what time did you last use cannabis? ____________ 
 
5. Have you had any caffeinated beverages today?   Yes No 
 
If you answered “yes”, at what time did you drink your last caffeinated beverage? ___________ 
 
6. Have you taken any medications (either prescription or over the counter) or used any illicit 
drugs since your last session?    Yes No 
 
If you answered “yes”, what were the medications and when did you take them?  
 
______________________________________________________________________ 
 
7. Have you been ill since your last session?   Yes No 
 
If you answered “yes”, please explain: _______________________________________ 
 
______________________________________________________________________ 
 
8. Have you experienced any changes in your usual routine since your last session?  
 
Yes No 
 
If you answered “yes”, please explain: _______________________________________ 
 
______________________________________________________________________ 
 
9. If female, when was the start date of your last menstrual cycle?  ________________  
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Appendix C. 
Study Run Sheet 
 
Study day  Practice  1 2 3 4 5 
Type of Cue       
Date             
               
Setup Materials:             
set-up session computer             
consent form             
urine collection cup              
pregnancy test             
               
Check-in procedure             
collect keys, watch, phone             
smoke break (Y/N)             
field sobriety test             
BAL % % % % % % 
CO ppm ppm ppm ppm ppm ppm 
weight lbs. lbs. lbs. lbs. lbs. lbs. 
sign in questionnaire             
urine screen (to run: negative 
for all but THC)   
    
      
pregnancy screen (to run: 
negative)             
               
0:00 
Assessment 1  
(record start time)             
 BP mmHg mmHg mmHg mmHg mmHg mmHg 
 HR bpm bpm bpm bpm bpm bpm 
                
 Cue Exposure             
                
 
Assessment 2  
(record start time)             
 BP mmHg mmHg mmHg mmHg mmHg mmHg 
 HR bpm bpm bpm bpm bpm bpm 
                
0:30 
Assessment 3  
(record start time)             
 BP mmHg mmHg mmHg mmHg mmHg mmHg 
 HR bpm bpm bpm bpm bpm bpm 
                
1:00 
Assessment 4  
(record start time)             
 BP mmHg mmHg mmHg mmHg mmHg mmHg 
 HR bpm bpm bpm bpm bpm bpm 
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 Check-Out Procedure             
 return keys, watch,  
cell phone             
 back-up data             
 Up date earnings sheet             
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Appendix D. 
Marijuana Craving Questionnaire – Short Form 
 
Indicate how strongly you agree or disagree with each of the following statements by selecting a 
number between 1 (STRONGLY DISAGREE) and 7 (STRONGLY AGREE). The closer your 
selection to one end or the other indicates the strength of your agreement or disagreement. If you 
don’t agree or disagree with a statement, select the mid-point number 4. Please complete every 
item. We are interested in how you are thinking or feeling right now as you are filling out the 
questionnaire. When you are done, click the “Next” button. 
 
Please answer the following questions based on how you are feeling RIGHT NOW: 
 
1. Smoking cannabis would be pleasant right now 
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE 
2. I could not easily limit how much cannabis I smoked right now 
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE 
3. Right now, I am making plans to use cannabis 
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE 
4. I would feel more in control of things right now if I could smoke cannabis 
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE 
5. Smoking cannabis would help me sleep better at night 
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE 
6. If I smoked cannabis right now, I would feel less tense 
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE 
7. I would not be able to control how much cannabis I smoked if I had some here 
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE 
8. It would be great to smoke cannabis right now 
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE 
9. I would feel less anxious if I smoked cannabis right now 
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE 
10. I need to smoke cannabis now 
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE 
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11. If I were smoking cannabis right now, I would feel less nervous 
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE 
12. Smoking cannabis would make me content.  
STRONGLY DISAGREE ____ : ____ : ____ : ____ : ____ : ____ : ____ STRONGLY AGREE 
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Appendix E. 
Visual Analog Scale 
 
A series of questions will be individually presented on the computer screen. Use the mouse to move 
the indicator to the place on the line, labeled “Not at all” on the left and “Extremely” on the right, 
which best indicates how you feel at the moment, and then click the mouse button. You can change 
your answer by repositioning the indicator along the line and clicking again. When you are done, 
click the “Next” button. 
 
Please answer the following questions based on how you are feeling RIGHT NOW: 
 
I feel… 
Sedated 
Stimulated 
Nauseated 
Shaky or Jittery 
Restless 
Dizzy 
Difficulty Concentrating 
Anxious 
Nervous 
 
I have a craving for… 
Alcohol 
Tobacco 
Marijuana 
Cocaine 
Opiates 
 
 
  
42 
 
Appendix F. 
Subject-Rated Physiological Questionnaire 
 
Indicate how aware you were of the following symptoms while handling the objects by selecting 
a number between 1 (NOT AT ALL) and 5 (ALL OF THE TIME). The closer your selection to 
one end or the other indicates the strength of your awareness. Please complete every item. We are 
interested in how you were thinking or feeling during the time you were handling the objects 
as you are filling out the questionnaire. When you are done, click the “Next” button.  
 
During the time you were handling the object, how much of the time were you aware of 
each? Click on the NEXT button to go to the next statement. 
 
1. Faster heart rate 
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME 
2. Rapid breathing 
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME 
3. Sweating hands 
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME 
4. Heavy feeling in the stomach 
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME 
5. Loud pounding heart 
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME 
6. Tensed muscles 
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME 
7. Cold hands 
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME 
8. Feeling flushed or hot 
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME 
9. Salivating more 
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME 
10. Trembling 
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME 
11. Dry mouth 
NOT AT ALL ____ : ____ : ____ : ____ : ____ ALL OF THE TIME 
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